Kite Pharma Inc. Cm (NASDAQ:KITE).
Omers Administration Corp lowered its stake in Kite Pharma Inc. Cm shares by 23.8% as of the end of the last quarter. Its investment stood at $2,769,000 an increase of $1,184,000 according to the filing.
Here are some institutional investors who have increased or decreased their stake in (KITE). As of quarter end Pinnacle Associates Ltd had sold a total of 7,172 shares trimming its position 3.0%. The value of the total investment in Kite Pharma Inc. Cm went from $25,078,000 to $42,207,000 a change of 68.3% quarter to quarter. Ubs Asset Management Americas Inc expanded its position by buying 674 shares an increase of 2,808.3% in the quarter. Ubs Asset Management Americas Inc now holds 698 shares worth $125,507,000. The value of the position overall is up by 4,944.5%.
Raymond James & Associates grew its investment by buying 478 shares an increase of 3.8% as of 09/30/2017. Raymond James & Associates controls 13,012 shares with a value of $2,340,000. The total value of its holdings increased 80.1%.
August 10 investment analysts at Stifel Nicolaus made no change to the stock rating of “Hold” with a current price target of $74.00.
The company is unchanged by % since yesterday’s close of 179.79. The P/E ratio is N/A and the market value is 10.28B. In the last earnings report the EPS was $-6.90 with 57.18M shares now outstanding.
Investors are more bullish on the company considering the change in short interest. The company realized a fall in short interest from September 15, 2017 to September 29, 2017 of -25.38%. Short shares fell from 3,262,218 to 2,434,148 over that timeframe. Days to cover decreased 0.0 to 1.0 and the percentage of shorted shares was 0.04% on September 29.